Home / Health / First in Sussex: New Prostate Cancer Drug Trial
First in Sussex: New Prostate Cancer Drug Trial
9 Apr
Summary
- A patient received an innovative Lutetium PSMA drug.
- The new treatment targets prostate cancer cells internally.
- This trial is the first of its kind in Sussex.
A groundbreaking clinical trial for advanced prostate cancer has commenced in Sussex, with Darius Aibara, 61, becoming the first patient in the region to receive a novel treatment. The specialized radiopharmaceutical drug, Lutetium PSMA, was administered at the Royal Sussex County Hospital in Brighton. This innovative therapy, part of a national trial, involves an intravenous drip that delivers targeted internal radiation directly to prostate cancer cells.
Aibara, a retired civil engineer, has already undergone four sessions of Lutetium PSMA treatment, alongside chemotherapy and hormone therapy, with further sessions planned. He expressed optimism about his progress, noting the painless nature of the treatment and the excellent care provided by the hospital team. The trial, supported by the Brighton and Hove-based Sussex Cancer Fund charity, also includes a high-precision form of radiotherapy for some participants. Professor Sabina Dizdarevic highlighted the trial's importance in developing more effective treatments for advanced prostate cancer.
